Bispecific antibody market report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics.
PORTLAND, OREGON, UNITED STATES, September 15, 2023/EINPresswire.com/ — Bispecific antibody market was valued at $5.5 billion in 2022, and is estimated to reach $109.4 billion by 2032, growing at a CAGR of 34.8% from 2023 to 2032. Bispecific antibodies are artificial proteins that have promising applications in the field of cancer and immunotherapy. They are comprised of two monoclonal antibodies which are held together by a flexible peptide linker. This makes them able to bind to two different antigens, as the name suggests. The unique properties of bispecific antibodies make them versatile therapeutic agents. They improve therapy effectiveness, target certain cell types, and address complex disease pathways. Bispecific antibodies act as a bridge between cancer cells and cytotoxic T lymphocytes (CTLs). They bind CD3 antigens on CTLs and a specific antigen on cancer cells, which in turn activates the T cells, promotes the lysis of cancer cells, and make bispecific antibody effective in cancer treatment.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Bristol-Myers Squibb Company, Merus, Regeneron Pharmaceuticals, Inc., Amgen Inc., Johnson & Johnson, AbbVie Inc, AstraZeneca plc, MacroGenics Inc., Pfizer Ltd, F. Hoffmann-La Roche Ltd.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/130431
On the basis of product, the bispecific antibody market size is classified into blinatumomab, emicizumab, and others. Others includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. The blinatumomab segment is expected to be the fastest-growing segment during the forecast period owing to the increase in incidences of leukemia and rise in technological advances in the field of cancer treatments.
On the basis of application, the bispecific antibody market analysis is classified into cancer, hemophilia, and others. Others include autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. The hemophilia segment is projected to be the fastest growing segment during the forecast period, owing to a rise in the number of populations suffering from hemophilia and increase in the awareness among the people regarding treatment of hemophilia.
On the basis of end user, the bispecific antibody market share is classified into hospitals, cancer centers, and others. The hospitals segment is projected to be the fastest growing segment during the forecast period owing to rise in the number of initiatives taken by government for development of healthcare infrastructure and rise in the prevalence of chronic diseases and autoimmune diseases.
On the basis of region, North America had the highest bispecific antibody market share in 2022 and is expected to maintain its lead during the forecast period owing to increase in prevalence of cancer, growth in demand for next-generation antibody therapeutics, and technological advancement in the healthcare sector. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to the fact that this region has large and growing population, which is susceptible to the rise in prevalence of infectious diseases, rise in the number of product approvals for bispecific antibodies and increase in the strategic partnership among the market players.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/130431
๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐๐:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on โStrategic Developmentsโ registered by leading players of the market
๐๐๐๐๐๐- ๐ ๐๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐๐ข๐๐ซ๐๐ซ๐ฒ (๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐จ๐ง-๐๐๐ฆ๐๐ง๐, ๐ฌ๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐ฉ๐ซ๐ข๐๐ข๐ง๐ ๐ฆ๐จ๐๐๐ฅ) ๐๐๐๐๐ซ๐๐ ๐๐ฒ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
๐๐๐ญ ๐๐ง ๐๐๐๐๐ฌ๐ฌ ๐ญ๐จ ๐ญ๐ก๐ ๐ฅ๐ข๐๐ซ๐๐ซ๐ฒ ๐จ๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ญ ๐๐ง๐ฒ ๐ญ๐ข๐ฆ๐ ๐๐ซ๐จ๐ฆ ๐๐ง๐ฒ ๐๐๐ฏ๐ข๐๐ ๐๐ง๐ ๐๐ง๐ฒ๐ฐ๐ก๐๐ซ๐. ๐ ๐จ๐ซ ๐ฆ๐จ๐ซ๐ ๐๐๐ญ๐๐ข๐ฅ๐ฌ, ๐๐จ๐ฅ๐ฅ๐จ๐ฐ ๐ญ๐ก๐ ๐ฅ๐ข๐ง๐ค: https://www.alliedmarketresearch.com/library-access
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
